Delix Therapeutics
Latest round
- Series A
Last raised
- Sep 2021
Total raised
- $80M
Investors
- 11
About Delix Therapeutics
Based in the US, Delix Therapeutics, Inc.Delix Therapeutics, Inc. is focused on creating innovative treatments for mental health issues through the development of neuroplastogens. The company is headquartered in Concord, US.Delix Therapeutics is pioneering a new class of therapeutics known as neuroplastogens, designed to enhance brain health. These compounds leverage the brain's inherent capacity for neuroplasticity, aiming to repair and improve the physical structure of brain cells. By doing so, Delix targets a variety of neuropsychiatric conditions, seeking to provide treatments that are safe, fast-acting, and long-lasting. The company’s core offerings focus on developing novel therapeutics that can alleviate prevalent mental health issues, thereby serving a diverse clientele, including healthcare providers and mental health practitioners.Delix Therapeutics operates with a focus on ensuring consistent revenue through partnerships with healthcare institutions and direct sales to medical facilities. The company’s transaction structure involves B2B relationships, where products are supplied to healthcare providers who then administer them to patients requiring mental health interventions. Revenue is generated through the sales of their flagship neuroplastogen compounds, which are integrated into treatment protocols by clinicians. The pricing structure reflects the premium nature of these therapeutics, aligning with the advanced scientific research and development backing the products. The company aims to grow its team and pursue additional strategic opportunities to enhance its market presence. Delix is also targeting expansion into new geographic regions to broaden access to its therapeutics, aiming to establish a foothold in additional markets by late 2023.
Who invested in Delix Therapeutics
11 investors across 2 rounds
See all investors in Delix Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Delix Therapeutics
Who invested in Delix Therapeutics?
Delix Therapeutics has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Delix Therapeutics raised?
Delix Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Delix Therapeutics last raise money?
Delix Therapeutics's most recent round on record is a Series A, in Sep 2021.
What does Delix Therapeutics do?
Based in the US, Delix Therapeutics, Inc.
Where is Delix Therapeutics headquartered?
Delix Therapeutics is headquartered in Concord, US.
Which VCs invest in companies like Delix Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Delix Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Delix Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.